Fig. 5
From: Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers
Foxo13A-NP-transfection improves the anti-cancer activities of CAR T-cells. NSG mice were inoculated with CD19 + Raji-luc tumor cells. After 7 days the mice were injected with luciferin and imaged on an IVIS before being randomly sorted into groups (n = 9) with representative tumor burden. Next 2.5 × 106 CD8+ 19-41BBζ CAR + T-cells (transfected with NPs loaded either with Foxo13A mRNA or GFP mRNA) were infused intravenously. Control mice received no treatment. a Representative IVIS imaging depicting five mice per cohort. b Quantified tumor burden (as mean radiance from luciferase activity from each mouse from a ± SE). Pairwise differences between groups were analyzed with the unpaired, two-tailed Student’s t Test; n.s., non-significant; *, significant. c Kaplan–Meier survival curves for treated and untreated control mice. Shown are nine mice per treatment group pooled from two independent experiments. ms, median survival. Statistical analysis between the treated experimental and the untreated control group was performed using the Log-rank test; P < 0.05 was considered significant
